Skip to main content
. 2011 Dec 30;2(12):1254–1264. doi: 10.18632/oncotarget.406

Figure 5. Validation of shRNAs targeting RARA and the effect of retinoids on the response of lung cancer cells to GSK461364A.

Figure 5

Panel A. Confirmation that the two shRNAs directed against RARA knockdown protein expression. NCI-H460 cells were stably infected with control vector (lane 1) or the two different shRNAs (lanes 2 and 3), and extracts were immunoblotted with anti-RARα antibody. Panel B. Dose-response curves showing the sensitivity of NCI-H460 cells to growth inhibition by GSK461364A that had been previously transduced with either control vector (blue line) or the two different shRNAs directed against RARA (red lines; each shRNA is shown in a separate graph). Panel C. Dose-response curves showing the sensitivity of four different lung cancer cell lines to varying concentrations of GSK461364A in the presence (red) or absence (blue) of 1 micromolar ATRA and 1 micromolar 9-cis-retinoic acid. 1,000-3,000 cells were plated in 96-well plates and assayed for growth inhibition as described in Methods.